Primary Myelodysplastic Syndromes. The Mayo Clinic Experience With 1000 Patients

Naseema Gangat, Mrinal M Patnaik, Kebede Begna, Taxiarchis Kourelis, Aref Al-Kali, Michelle A. Elliott, William Hogan, Louis Letendre, Mark R Litzow, Ryan A. Knudson, Rhett P. Ketterling, Janice M. Hodnefield, Curtis A. Hanson, Animesh D Pardanani, Ayalew Tefferi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objectives: To share our 25 years of experience with patients with primary myelodysplastic syndromes (MDS) and to describe the natural history of the disease including presenting clinical and laboratory characteristics and long-term disease outcomes. Patients and Methods: One thousand consecutive patients with primary MDS evaluated at Mayo Clinic between January 1, 1989, and May 1, 2014, were considered. The Revised International Prognostic Scoring System and other risk models were applied for risk stratification. Separate analyses were conducted for patients diagnosed before 2005 (n=531) and after 2005 (n=469). Results: Eighty-five percent of patients were older than 60 years (median age, 72 years), with 69% being men. The median follow-up period was 27 months (range, 0-300 months), during which time 808 (81%) deaths and 129 (13%) leukemic transformations were documented. Median survival and leukemic transformation rates were similar in patients diagnosed before or after 2005, despite the significantly higher use of hypomethylating agents in the latter group: 33 months vs 28 months (P = 46) and 13% vs 10% (P = 92), respectively. Revised International Prognostic Scoring System risk distribution was similar in patients diagnosed before or after 2005 (P = 23): 17% were categorized as very low, 36% low, 21% intermediate, 15% high, and 11% very high risk, with a median survival of 72, 43, 24, 18, and 7 months, respectively (P

Original languageEnglish (US)
JournalMayo Clinic Proceedings
DOIs
StateAccepted/In press - 2015

Fingerprint

Myelodysplastic Syndromes
Pyridinolcarbamate
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Primary Myelodysplastic Syndromes. The Mayo Clinic Experience With 1000 Patients. / Gangat, Naseema; Patnaik, Mrinal M; Begna, Kebede; Kourelis, Taxiarchis; Al-Kali, Aref; Elliott, Michelle A.; Hogan, William; Letendre, Louis; Litzow, Mark R; Knudson, Ryan A.; Ketterling, Rhett P.; Hodnefield, Janice M.; Hanson, Curtis A.; Pardanani, Animesh D; Tefferi, Ayalew.

In: Mayo Clinic Proceedings, 2015.

Research output: Contribution to journalArticle

Gangat, Naseema ; Patnaik, Mrinal M ; Begna, Kebede ; Kourelis, Taxiarchis ; Al-Kali, Aref ; Elliott, Michelle A. ; Hogan, William ; Letendre, Louis ; Litzow, Mark R ; Knudson, Ryan A. ; Ketterling, Rhett P. ; Hodnefield, Janice M. ; Hanson, Curtis A. ; Pardanani, Animesh D ; Tefferi, Ayalew. / Primary Myelodysplastic Syndromes. The Mayo Clinic Experience With 1000 Patients. In: Mayo Clinic Proceedings. 2015.
@article{1178898c6bfa4297a8595a3fac008730,
title = "Primary Myelodysplastic Syndromes. The Mayo Clinic Experience With 1000 Patients",
abstract = "Objectives: To share our 25 years of experience with patients with primary myelodysplastic syndromes (MDS) and to describe the natural history of the disease including presenting clinical and laboratory characteristics and long-term disease outcomes. Patients and Methods: One thousand consecutive patients with primary MDS evaluated at Mayo Clinic between January 1, 1989, and May 1, 2014, were considered. The Revised International Prognostic Scoring System and other risk models were applied for risk stratification. Separate analyses were conducted for patients diagnosed before 2005 (n=531) and after 2005 (n=469). Results: Eighty-five percent of patients were older than 60 years (median age, 72 years), with 69{\%} being men. The median follow-up period was 27 months (range, 0-300 months), during which time 808 (81{\%}) deaths and 129 (13{\%}) leukemic transformations were documented. Median survival and leukemic transformation rates were similar in patients diagnosed before or after 2005, despite the significantly higher use of hypomethylating agents in the latter group: 33 months vs 28 months (P = 46) and 13{\%} vs 10{\%} (P = 92), respectively. Revised International Prognostic Scoring System risk distribution was similar in patients diagnosed before or after 2005 (P = 23): 17{\%} were categorized as very low, 36{\%} low, 21{\%} intermediate, 15{\%} high, and 11{\%} very high risk, with a median survival of 72, 43, 24, 18, and 7 months, respectively (P",
author = "Naseema Gangat and Patnaik, {Mrinal M} and Kebede Begna and Taxiarchis Kourelis and Aref Al-Kali and Elliott, {Michelle A.} and William Hogan and Louis Letendre and Litzow, {Mark R} and Knudson, {Ryan A.} and Ketterling, {Rhett P.} and Hodnefield, {Janice M.} and Hanson, {Curtis A.} and Pardanani, {Animesh D} and Ayalew Tefferi",
year = "2015",
doi = "10.1016/j.mayocp.2015.08.022",
language = "English (US)",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",

}

TY - JOUR

T1 - Primary Myelodysplastic Syndromes. The Mayo Clinic Experience With 1000 Patients

AU - Gangat, Naseema

AU - Patnaik, Mrinal M

AU - Begna, Kebede

AU - Kourelis, Taxiarchis

AU - Al-Kali, Aref

AU - Elliott, Michelle A.

AU - Hogan, William

AU - Letendre, Louis

AU - Litzow, Mark R

AU - Knudson, Ryan A.

AU - Ketterling, Rhett P.

AU - Hodnefield, Janice M.

AU - Hanson, Curtis A.

AU - Pardanani, Animesh D

AU - Tefferi, Ayalew

PY - 2015

Y1 - 2015

N2 - Objectives: To share our 25 years of experience with patients with primary myelodysplastic syndromes (MDS) and to describe the natural history of the disease including presenting clinical and laboratory characteristics and long-term disease outcomes. Patients and Methods: One thousand consecutive patients with primary MDS evaluated at Mayo Clinic between January 1, 1989, and May 1, 2014, were considered. The Revised International Prognostic Scoring System and other risk models were applied for risk stratification. Separate analyses were conducted for patients diagnosed before 2005 (n=531) and after 2005 (n=469). Results: Eighty-five percent of patients were older than 60 years (median age, 72 years), with 69% being men. The median follow-up period was 27 months (range, 0-300 months), during which time 808 (81%) deaths and 129 (13%) leukemic transformations were documented. Median survival and leukemic transformation rates were similar in patients diagnosed before or after 2005, despite the significantly higher use of hypomethylating agents in the latter group: 33 months vs 28 months (P = 46) and 13% vs 10% (P = 92), respectively. Revised International Prognostic Scoring System risk distribution was similar in patients diagnosed before or after 2005 (P = 23): 17% were categorized as very low, 36% low, 21% intermediate, 15% high, and 11% very high risk, with a median survival of 72, 43, 24, 18, and 7 months, respectively (P

AB - Objectives: To share our 25 years of experience with patients with primary myelodysplastic syndromes (MDS) and to describe the natural history of the disease including presenting clinical and laboratory characteristics and long-term disease outcomes. Patients and Methods: One thousand consecutive patients with primary MDS evaluated at Mayo Clinic between January 1, 1989, and May 1, 2014, were considered. The Revised International Prognostic Scoring System and other risk models were applied for risk stratification. Separate analyses were conducted for patients diagnosed before 2005 (n=531) and after 2005 (n=469). Results: Eighty-five percent of patients were older than 60 years (median age, 72 years), with 69% being men. The median follow-up period was 27 months (range, 0-300 months), during which time 808 (81%) deaths and 129 (13%) leukemic transformations were documented. Median survival and leukemic transformation rates were similar in patients diagnosed before or after 2005, despite the significantly higher use of hypomethylating agents in the latter group: 33 months vs 28 months (P = 46) and 13% vs 10% (P = 92), respectively. Revised International Prognostic Scoring System risk distribution was similar in patients diagnosed before or after 2005 (P = 23): 17% were categorized as very low, 36% low, 21% intermediate, 15% high, and 11% very high risk, with a median survival of 72, 43, 24, 18, and 7 months, respectively (P

UR - http://www.scopus.com/inward/record.url?scp=84953319355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953319355&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2015.08.022

DO - 10.1016/j.mayocp.2015.08.022

M3 - Article

C2 - 26546107

AN - SCOPUS:84953319355

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

ER -